News
Eckert & Ziegler unter Abgabedruck: Die Alternative?!
Die Aktie von Eckert & Ziegler (WKN: 565970) steht heute unter Abgabedruck, nachdem das deutsche Vorzeige-Medizintechnikunternehmen seine aktuellen Quartalszahlen vorgelegt hat. Denn diese fielen
Sartorius: Unternehmen profitiert von der Corona-Krise
Ein absoluter Highflyer am deutschen Aktienmarkt ist schon seit vielen Jahren die Vorzugsaktie des Göttinger Laborausrüsters Sartorius (WKN: 716563). Dies ist umso erstaunlicher, da noch zu Neuer
Gilead Sciences: Wer wird nun der nächste Corona-Gewinner?
Auf dem US-Konzern Gilead Sciences (WKN: 885823) und dem Wirkstoff Remdesivir liegen die Hoffnungen vieler Anleger. Doch Medikamente und Impstoffe sind nicht die einzigen Corona-Profiteure.
Xencor Announces Proposed Public Offering of Common Stock
Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it
Dexcom CGM Worn in Outer Space as Part of First-of-its-Kind Polaris Dawn Mission
DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being
EQS-News: Abivax presents first-half 2024 financial results
Agilent Unveils Biopharma CDx Services Lab to Accelerate Precision Medicine
Agilent Technologies Inc., (NYSE: A) today announced the launch of its Biopharma CDx Services Lab (BCSL) in Carpinteria, California, following receipt of California State clinical laboratory
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
Novocure (NASDAQ: NVCR) announced today it will present a real-world analysis of usage of its Tumor Treating Fields (TTFields) therapy and survival outcomes in newly diagnosed glioblastoma (ndGBM)
Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced four new XmAb®
Owens & Minor to Present at the 2024 Baird Global Healthcare Conference
Owens & Minor, Inc. (NYSE: OMI), announced today that Ed Pesicka, the Company’s President and Chief Executive Officer and Jon Leon, Corporate Treasurer and interim Chief Financial Officer, will
Poxel Reports Revenue for the Second Quarter and First Half 2024 and Provides Corporate Update
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that new data from the Phase 3 IMPALA-2 clinical trial of
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.
On September 5
Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that management will
Inogen Appoints Eric Pauls as Vice President of Sales, North America
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Eric Pauls as Vice President
Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) announced today that the first participant has been dosed in a Phase 1a single ascending dose (SAD) study of AUR200, a
EQS-News: Preliminary IFRS result for the first half of 2024 EBIT increases significantly to 75.7 mn euros. Equity increases by EUR 74.5 mn to EUR 325.5 mn, which corresponds to EUR 76.02 per share.
EQS-Adhoc: MeVis Medical Solutions AG: Adjusting forecast for the current fiscal year
Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience
Charles River Laboratories International, Inc. (NYSE: CRL) and Insightec, a global healthcare company dedicated to using focused ultrasound to transform patient care, today announced the launch of
Dexcom to Showcase Transformational Impact of Dexcom CGM Technology at the EASD 2024 Conference Symposium
DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will spotlight the significant benefits of its innovative CGM technology at
EQS-News: Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
EGS Beteiligungen AG exercises right to convert bond and increases its shareholding in Siegfried to 7.2% registered shares
Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C
Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of the
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including:
-
Morgan Stanley 22nd Annual Global Healthcare